Weight Loss Results / Food Cravings: 4.5/5 After one month, I noticed a reduction in appetite for sweets and treats, which helped me lose weight
New research reveals how GLP-1 receptor drugs, known for treating diabetes and obesity, also protect the brains vital neurovascular system, offering hope for tackling cognitive decline and neurodegenerative diseases like Alzheimer's
67 PEG-loxenatide, Chinas first long-acting GLP-RA product, was approved for marketing in China in May 2019
By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
The results showed that abdominal fat percentage decreased by 2.6, 2.8, and 6.1 percentage points in the exercise, Lira, and combination groups compared to placebo
The gradual dose escalation protocols are specifically designed to minimise these effects
